Yoshihide Inayama, Ken Yamaguchi, Kayoko Mizuno, Sachiko Tanaka-Mizuno, Ayami Koike, Nozomi Higashiyama, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Junzo Hamanishi, Satomi Yoshida, Masaki Mandai, Koji Kawakami
{"title":"生活日志数据表明,癌症诊断和治疗期间身体活动减少:使用与日本索赔数据库相关的智能手机步数数据进行分析。","authors":"Yoshihide Inayama, Ken Yamaguchi, Kayoko Mizuno, Sachiko Tanaka-Mizuno, Ayami Koike, Nozomi Higashiyama, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Junzo Hamanishi, Satomi Yoshida, Masaki Mandai, Koji Kawakami","doi":"10.2196/58093","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although physical activity (PA) is recommended for patients with cancer, changes in PA across cancer diagnosis and treatment have not been objectively evaluated.</p><p><strong>Objective: </strong>This study aimed to assess the impact of cancer diagnosis and treatment on PA levels.</p><p><strong>Methods: </strong>This was a retrospective cohort study using a Japanese claims database provided by DeSC Healthcare Inc, in which daily step count data, derived from smartphone pedometers, are linked to the claims data. In this study, we included patients newly diagnosed with cancer, along with those newly diagnosed with diabetes mellitus for reference. We collected data between April 2014 and September 2021 and analyzed them. The observation period spanned from 6 months before diagnosis to 12 months after diagnosis. We applied a generalized additive mixed model with a cubic spline to describe changes in step counts before and after diagnosis.</p><p><strong>Results: </strong>We analyzed the step count data of 326 patients with malignant solid tumors and 1388 patients with diabetes. Patients with cancer exhibited a 9.6% (95% CI 7.1%-12.1%; P<.001) reduction in step counts from baseline at the start of the diagnosis month, which further deepened to 12.4% (95% CI 9.5%-15.2%; P<.001) at 3 months and persisted at 7.1% (95% CI 4.2%-10.0%; P<.001) at 12 months, all relative to baseline. Conversely, in patients with diabetes, step counts remained relatively stable after diagnosis, with a slight upward trend, resulting in a change of +0.6% (95% CI -0.6% to 1.9%; P=.31) from baseline at 3 months after diagnosis. At 12 months after diagnosis, step counts remained decreased in the nonendoscopic subdiaphragmatic surgery group, with an 18.0% (95% CI 9.1%-26.2%; P<.001) reduction, whereas step counts returned to baseline in the laparoscopic surgery group (+0.3%, 95% CI -6.3% to 7.5%; P=.93).</p><p><strong>Conclusions: </strong>The analysis of objective pre- and postdiagnostic step count data provided fundamental information crucial for understanding changes in PA among patients with cancer. While cancer diagnosis and treatment reduced PA, the decline may have already started before diagnosis. The study findings may help tailor exercise recommendations based on lifelog data for patients with cancer in the future.</p>","PeriodicalId":45538,"journal":{"name":"JMIR Cancer","volume":" ","pages":"e58093"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Changes in Physical Activity Across Cancer Diagnosis and Treatment Based on Smartphone Step Count Data Linked to a Japanese Claims Database: Retrospective Cohort Study.\",\"authors\":\"Yoshihide Inayama, Ken Yamaguchi, Kayoko Mizuno, Sachiko Tanaka-Mizuno, Ayami Koike, Nozomi Higashiyama, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Junzo Hamanishi, Satomi Yoshida, Masaki Mandai, Koji Kawakami\",\"doi\":\"10.2196/58093\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Although physical activity (PA) is recommended for patients with cancer, changes in PA across cancer diagnosis and treatment have not been objectively evaluated.</p><p><strong>Objective: </strong>This study aimed to assess the impact of cancer diagnosis and treatment on PA levels.</p><p><strong>Methods: </strong>This was a retrospective cohort study using a Japanese claims database provided by DeSC Healthcare Inc, in which daily step count data, derived from smartphone pedometers, are linked to the claims data. In this study, we included patients newly diagnosed with cancer, along with those newly diagnosed with diabetes mellitus for reference. We collected data between April 2014 and September 2021 and analyzed them. The observation period spanned from 6 months before diagnosis to 12 months after diagnosis. We applied a generalized additive mixed model with a cubic spline to describe changes in step counts before and after diagnosis.</p><p><strong>Results: </strong>We analyzed the step count data of 326 patients with malignant solid tumors and 1388 patients with diabetes. Patients with cancer exhibited a 9.6% (95% CI 7.1%-12.1%; P<.001) reduction in step counts from baseline at the start of the diagnosis month, which further deepened to 12.4% (95% CI 9.5%-15.2%; P<.001) at 3 months and persisted at 7.1% (95% CI 4.2%-10.0%; P<.001) at 12 months, all relative to baseline. Conversely, in patients with diabetes, step counts remained relatively stable after diagnosis, with a slight upward trend, resulting in a change of +0.6% (95% CI -0.6% to 1.9%; P=.31) from baseline at 3 months after diagnosis. At 12 months after diagnosis, step counts remained decreased in the nonendoscopic subdiaphragmatic surgery group, with an 18.0% (95% CI 9.1%-26.2%; P<.001) reduction, whereas step counts returned to baseline in the laparoscopic surgery group (+0.3%, 95% CI -6.3% to 7.5%; P=.93).</p><p><strong>Conclusions: </strong>The analysis of objective pre- and postdiagnostic step count data provided fundamental information crucial for understanding changes in PA among patients with cancer. While cancer diagnosis and treatment reduced PA, the decline may have already started before diagnosis. The study findings may help tailor exercise recommendations based on lifelog data for patients with cancer in the future.</p>\",\"PeriodicalId\":45538,\"journal\":{\"name\":\"JMIR Cancer\",\"volume\":\" \",\"pages\":\"e58093\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JMIR Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2196/58093\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/58093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:虽然癌症患者被推荐进行体育锻炼,但在癌症诊断和治疗过程中体育锻炼的变化尚未得到客观评价。目的:探讨癌症诊断和治疗对身体活动水平的影响。方法:这是一项回顾性队列研究,使用由DeSC Healthcare Inc.提供的日本索赔数据库,其中每日步数数据来自智能手机计步器,与索赔数据相关联。在本研究中,我们纳入了新诊断为癌症的患者,以及新诊断为糖尿病的患者作为参考。我们收集了2014年4月至2021年9月的数据并进行了分析。观察期为诊断前6个月至诊断后12个月。我们应用了一个广义的三次样条加性混合模型来描述诊断前后步数的变化。结果:我们分析了326例恶性实体瘤患者和1388例糖尿病患者的步数数据。在诊断月开始时,癌症患者的步数比基线减少了9.6%[95%置信区间(CI) 7.1%, 12.1%;P < .001], 3个月时进一步加深至12.4% [95% CI 9.5%, 15.2%;P < .001],并在12个月时持续为7.1% [95% CI 4.2%, 10.0%;P < 0.001],均相对于基线。相反,在糖尿病患者中,诊断后步数保持相对稳定,有轻微上升趋势,在诊断后3个月较基线变化+0.6% [95% CI -0.6%, +1.9%;P = .31]。在诊断后12个月,非内窥镜下膈下手术组的步数仍然减少,减少18.0% [95% CI 9.1%, 26.2%;P < .001],而腹腔镜手术组的步数恢复到基线(+0.3% [95% CI -6.3%, 7.5%;P = .93])。结论:对诊断前和诊断后的客观步数数据的分析为了解癌症患者身体活动的变化提供了至关重要的基础信息。虽然癌症诊断和治疗减少了身体活动,但这种减少可能在诊断之前就已经开始了。这项研究结果可能有助于未来癌症患者根据生活日志数据量身定制锻炼建议。临床试验:
Changes in Physical Activity Across Cancer Diagnosis and Treatment Based on Smartphone Step Count Data Linked to a Japanese Claims Database: Retrospective Cohort Study.
Background: Although physical activity (PA) is recommended for patients with cancer, changes in PA across cancer diagnosis and treatment have not been objectively evaluated.
Objective: This study aimed to assess the impact of cancer diagnosis and treatment on PA levels.
Methods: This was a retrospective cohort study using a Japanese claims database provided by DeSC Healthcare Inc, in which daily step count data, derived from smartphone pedometers, are linked to the claims data. In this study, we included patients newly diagnosed with cancer, along with those newly diagnosed with diabetes mellitus for reference. We collected data between April 2014 and September 2021 and analyzed them. The observation period spanned from 6 months before diagnosis to 12 months after diagnosis. We applied a generalized additive mixed model with a cubic spline to describe changes in step counts before and after diagnosis.
Results: We analyzed the step count data of 326 patients with malignant solid tumors and 1388 patients with diabetes. Patients with cancer exhibited a 9.6% (95% CI 7.1%-12.1%; P<.001) reduction in step counts from baseline at the start of the diagnosis month, which further deepened to 12.4% (95% CI 9.5%-15.2%; P<.001) at 3 months and persisted at 7.1% (95% CI 4.2%-10.0%; P<.001) at 12 months, all relative to baseline. Conversely, in patients with diabetes, step counts remained relatively stable after diagnosis, with a slight upward trend, resulting in a change of +0.6% (95% CI -0.6% to 1.9%; P=.31) from baseline at 3 months after diagnosis. At 12 months after diagnosis, step counts remained decreased in the nonendoscopic subdiaphragmatic surgery group, with an 18.0% (95% CI 9.1%-26.2%; P<.001) reduction, whereas step counts returned to baseline in the laparoscopic surgery group (+0.3%, 95% CI -6.3% to 7.5%; P=.93).
Conclusions: The analysis of objective pre- and postdiagnostic step count data provided fundamental information crucial for understanding changes in PA among patients with cancer. While cancer diagnosis and treatment reduced PA, the decline may have already started before diagnosis. The study findings may help tailor exercise recommendations based on lifelog data for patients with cancer in the future.